ArticleCirculation reports2019
Urgent Control of Rapid Atrial Fibrillation by Landiolol in Patients With Acute Decompensated Heart Failure With Severely Reduced Ejection Fraction.
Article in Circulation reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Use of landiolol in septic shock patients with new onset of atrial fibrillation: a European Delphi consensus.Critical care (London, England) · 2026Article
- Treatment of supraventricular arrhythmias in critical care patients with sepsis.Frontiers in cardiovascular medicine · 2026Review
- The controversies in the clinical management of β-blockers in acute heart failure induced by rapid atrial fibrillation: A narrative review.American heart journal plus : cardiology research and practice · 2025Review
- Advances and controversies in acute decompensated heart failure treatment: beta-blocker roles, emerging devices, and future directions.Annals of medicine and surgery (2012) · 2025Review
- Landiolol bolus application for tachycardic dysrhythmia in the prehospital EMS setting - An observational study of a novel concept.Scandinavian journal of trauma, resuscitation and emergency medicine · 2025Observational
- Comparison of Landiolol and Esmolol on Haemodynamic Responses During Weaning of Intensive Care Unit Patients with Reduced Ejection Fraction after Vascular Surgery.Cardiac failure review · 2025Article
- Article
- An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation.Pharmaceutics · 2024Review
- Intravenous Landiolol for Rate Control in Supraventricular Tachyarrhythmias in Patients with Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- The Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department.Medicina (Kaunas, Lithuania) · 2023Review
- The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature.European heart journal supplements : journal of the European Society of Cardiology · 2022Article
- Benefits and safety of landiolol for rapid rate control in patients with atrial tachyarrhythmias and acute decompensated heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2022Article
- Acute rate control in atrial fibrillation: an urgent need for the clinician.European heart journal supplements : journal of the European Society of Cardiology · 2022Article
- Frequency of Atrial Fibrillation in Patients Presenting With Decompensated Heart Failure.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.